# Supriya Lifescience (NSE: SUPRIYA) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/SUPRIYA · Pivot · prices to 22 Oct 2026

Supriya Lifescience (NSE: SUPRIYA) closed at ₹848.80 on 22 Oct 2026, down 0.02% on the day. With a market capitalisation of ₹6,831 Cr, it ranks 670th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Biotechnology.

At its last close the stock traded at 32.7× trailing earnings, against a return on equity of 17.5% in FY26. Over the past year the share price has risen 19.4%. Its 52-week range is ₹545.50 (24 Mar 2026) to ₹1,085.00 (1 Jun 2026); the last close is 21.8% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹592 Cr (+15.6% year on year) and net profit −₹59 Cr, on a consolidated basis. Promoters held 68.30% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹848.80 |
| Market cap | ₹6,831 Cr |
| P/E (trailing) | 32.7 |
| ROE | 17.5% (FY26) |
| ROCE | 22.4% (FY26) |
| Debt to equity | 0 |
| 52-week high | ₹1,085.00 (1 Jun 2026) |
| 52-week low | ₹545.50 (24 Mar 2026) |
| 1-year return | +19.4% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹592 Cr | +15.6% | −₹59 Cr | — | −₹26.91 |
| Q4 FY26 | ₹518 Cr | −11.7% | ₹426 Cr | +197.1% | ₹193.42 |
| Q3 FY26 | ₹501 Cr | −5.3% | −₹52 Cr | — | −₹23.55 |
| Q2 FY26 | ₹495 Cr | −12.1% | −₹65 Cr | — | −₹29.19 |
| Q1 FY26 | ₹512 Cr | −11.9% | −₹58 Cr | — | −₹26.20 |
| Q4 FY25 | ₹587 Cr | +5.8% | ₹143 Cr | — | ₹68.03 |
| Q3 FY25 | ₹529 Cr | −3.9% | −₹44 Cr | — | −₹20.34 |
| Q2 FY25 | ₹563 Cr | +89.9% | −₹54 Cr | — | −₹26.79 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹696 Cr | ₹188 Cr |
| FY24 | ₹570 Cr | ₹119 Cr |
| FY23 | ₹461 Cr | ₹90 Cr |
| FY22 | ₹530 Cr | ₹152 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 68.30%
- Foreign institutions: 6.19%
- Domestic institutions: 5.30%
- Non-institutions: 20.21%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Thyrocare Technologies](https://app.pivotnow.in/stock/THYROCARE) | ₹470.65 | ₹7,491 Cr | 46.2 | — |
| [Morepen Laboratories](https://app.pivotnow.in/stock/MOREPENLAB) | ₹125.70 | ₹6,888 Cr | 72.7 | — |
| [Bliss GVS Pharma](https://app.pivotnow.in/stock/BLISSGVS) | ₹638.00 | ₹6,766 Cr | 53.1 | — |
| [Sanofi India](https://app.pivotnow.in/stock/SANOFI) | ₹2,845.00 | ₹6,552 Cr | 21.2 | — |
| [Entero Healthcare Solutions](https://app.pivotnow.in/stock/ENTERO) | ₹1,504.20 | ₹6,547 Cr | 57.1 | — |
| [Kovai Medical Center & Hospital](https://app.pivotnow.in/stock/KOVAI) | ₹5,738.00 | ₹6,279 Cr | 25.7 | — |

## Questions and answers

### What is the share price of Supriya Lifescience today?

Supriya Lifescience (NSE: SUPRIYA) last closed at ₹848.80 on 22 Oct 2026. Its 52-week high is ₹1,085.00 and its 52-week low is ₹545.50.

### What is the market cap of Supriya Lifescience?

Supriya Lifescience's market capitalisation is ₹6,831 Cr (₹6,831 Cr) at the 22 Oct 2026 close, ranking 670th among the NSE companies Pivot tracks.

### What is the P/E ratio of Supriya Lifescience?

Supriya Lifescience trades at a trailing P/E of 32.7. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 53.1.

### What is the ROE and ROCE of Supriya Lifescience?

Return on equity was 17.5% in FY26 and return on capital employed was 22.4% in FY26 (standalone figures).

### Is Supriya Lifescience a debt-free company?

Supriya Lifescience is close to debt-free: its debt-to-equity ratio was 0 in FY26.

### What were Supriya Lifescience's latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Supriya Lifescience reported revenue of ₹592 Cr, +15.6% year on year, and net profit of −₹59 Cr.

### How has Supriya Lifescience stock performed over the last year?

Supriya Lifescience's share price has risen 19.4% over the past year, +0.8% over three months and −11.6% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Supriya Lifescience?

As of 30 Jun 2026: promoters 68.30%, foreign institutions 6.19%, domestic institutions 5.30%, non-institutions 20.21%.

### Who are Supriya Lifescience's competitors?

The listed Pharma & Healthcare companies closest to Supriya Lifescience by market cap are Thyrocare Technologies, Morepen Laboratories, Bliss GVS Pharma, Sanofi India, Entero Healthcare Solutions and Kovai Medical Center & Hospital.

### Is Supriya Lifescience a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Supriya Lifescience's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SUPRIYA against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.